And so, the middle of the week has arrived. Climb every mountain, as they say. And to that, we add you should do so with a cup of stimulation in hand. So please join us as we quaff a few and, of course, get ready for another busy, busy day. After all, meetings and deadlines and what-not await. So time to dig in. Here are some tidbits to get you started. Have a grand day and do stay in touch...
Pharma Execs Warn US Must Reverse Cuts To Science Investment (Forbes)
Royalty Pharma To Meet Elan investors About Bid (Bloomberg News)
Glaxo Prepares To Relaunch Direct Selling Channel (Marketing Week)
FDA Panel Nixes Calcitonin Salmon For Osteoperosis (Reuters)
AstraZeneca And Targacept Restructure Development Deal (Winston Salem-Journal)
Takeda Put Actos Sales Ahead Of Safety, Witness Says (Bloomberg News)
Drug Study Recruiting At University Of Minnesota Questioned (Star-Tribune)
ABPI CEO Has A Tin Ear For The AllTrials Campaign (The Guardian)
EU Approves Roche Perjeta Drug For Breast Cancer (Pharma Times)
Ranbaxy Labs To Sell Generic Pristiq (Associated Press)
MHRA: API Inspections Will Not Solve Shortage Concerns (InPharma Technologist)
Zeotis To Move HQ To Different NJ Location (Daily Record)
Impax Labs Stock Falls After FDA Finds New Problems (Associated Press)
EDITOR'S NOTE: Please check this post for additional items during the day
snowfall pic thx to mdid on flickr